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Abstract 
Background: Highly chemically similar drugs usually possess similar biological activities, but sometimes, small 
changes in chemistry can result in a large difference in biological effects. Chemically similar drug pairs that show 
extreme deviations in activity represent distinctive drug interactions having important implications. These associations 
between chemical and biological similarity are studied as discontinuities in activity landscapes. Particularly, activity 
cliffs are quantified by the drop in similar activity of chemically similar drugs. In this paper, we construct a landscape 
using a large drug-target network and consider the rises in similarity and variation in activity along the chemical 
space. Detailed analysis of structure and activity gives a rigorous quantification of distinctive pairs and the probability 
of their occurrence.
Results: We analyze pairwise similarity (s) and variation (d) in activity of drugs on proteins. Interactions between 
drugs are quantified by considering pairwise s and d weights jointly with corresponding chemical similarity (c) 
weights. Similarity and variation in activity are measured as the number of common and uncommon targets of two 
drugs respectively. Distinctive interactions occur between drugs having high c and above (below) average d (s). Com-
putation of predicted probability of distinctiveness employs joint probability of c, s and of c, d assuming independ-
ence of structure and activity. Predictions conform with the observations at different levels of distinctiveness. Results 
are validated on the data used and another drug ensemble. In the landscape, while s and d decrease as c increases, 
d maintains value more than s. c ∈ [0.3, 0.64] is the transitional region where rises in d are significantly greater than 
drops in s. It is fascinating that distinctive interactions filtered with high d and low s are different in nature. It is crucial 
that high c interactions are more probable of having above average d than s. Identification of distinctive interactions 
is better with high d than low s. These interactions belong to diverse classes. d is greatest between drugs and analogs 
prepared for treatment of same class of ailments but with different therapeutic specifications. In contrast, analogs 
having low s would treat ailments from distinct classes.
Conclusions: Intermittent spikes in d along the axis of c represent canyons in the activity landscape. This new repre-
sentation accounts for distinctiveness through relative rises in s and d. It provides a mathematical basis for predicting 
the probability of occurrence of distinctiveness. It identifies the drug pairs at varying levels of distinctiveness and 
non-distinctiveness. The predicted probability formula is validated even if data approximately satisfy the conditions 
of its construction. Also, the postulated independence of structure and activity is of little significance to the overall 
assessment. The difference in distinctive interactions obtained by s and d highlights the importance of studying both 
of them, and reveals how the choice of measurement can affect the interpretation. The methods in this paper can be 
used to interpret whether or not drug interactions are distinctive and the probability of their occurrence. Practitioners 
and researchers can rely on this identification for quantitative modeling and assessment.
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Background
The structural features of a drug compound describe its 
physicochemical properties that determine its biological 
activity on protein targets [1–4]. A vast number of com-
binations or analogs that result from small changes in 
chemical structure may not contribute to the diversity in 
biological activity or functionality of drugs. According to 
the similarity principle, structurally similar drugs tend to 
possess similar activity profiles, meaning that they would 
behave similarly on a particular protein [5, 6]. In addi-
tion, the impact of subjectivity in the decision making 
of medicinal chemists is known [7]. Thus the synthesis 
of new drugs, by introducing modifications in chemical 
compositions, is a complex process. The clinical phases 
of drug preparation are known to focus on a few prop-
erties [3, 4] but little is known about how the chemical 
structure is associated with biological activity of drugs. 
As established previously for drug target data, few drugs 
are active on many more targets than average while a 
large number of drugs are active on much fewer targets 
[8, 9]. This points to the discovery of certain molecular 
combinations having highly versatile functionalities. On 
the other hand, if targets are sufficiently distinct in their 
chemical nature, then the high druggability of few targets 
points to low specificity of a large number of medicines. 
Dissimilarity in activities of drugs when measured pair-
wise, often reveals pairs of drugs with highly dissimi-
lar activity. The pairwise associations or interactions of 
drugs are quantified with their chemical similarity and 
similarity or dissimilarity in their activities. Is variation 
in activity of drugs necessarily based on their chemical 
structures?
Medicinal chemistry has relied on the similarity prin-
ciple [3–6]. It implies that two structurally similar 
medicines tend to have similar (if not identical) activ-
ity profiles. However, many exceptions are known. For 
instance, chemically analogous tricyclic compounds 
Promethazine, Chlorpromazine, Imipramine pos-
sess distinct therapeutics [1, 2]. Highly similar PPAR-G 
drugs—Rosiglitazone and Troglitazone have very differ-
ent side-effect and adverse event profiles. Development 
of medicines and analogs with many targets facilitates 
the production of multipurpose medicines. It also leads 
to the emergence of activity cliffs [10–12], specifying 
pairs of structurally similar drugs having highly variant 
biological activities. These cliff-like interactions between 
drugs show extreme behaviors of pairs of chemically sim-
ilar drugs showing unusually large deviations in activi-
ties. They are quantified by the drop in similar activity 
of two drugs. However, one may use the rise in pairwise 
variation of their activities instead. Therefore, effectively 
such interactions between pairs of drugs can be termed 
as distinctive. The distinctiveness can be measured as the 
either the drop in similar activity or rise in variant activ-
ity of two drugs. In this paper, we develop a quantitative 
method to predict the probability of finding distinctive 
interactions using these measures and try to interpret 
them.
Activity landscape of drugs or the pharmacologi-
cal topography is a two-dimensional space of chemical 
structure and activity to which a pair of drugs can be 
mapped. In any landscape, the activity cliffs are repre-
sented as discontinuities occurring due to distinct drops 
in similar activity of chemically similar drugs. These are 
distinctive drug interactions studied with great inter-
est. Here, we analyze them using topographical features 
of the landscape. Researchers have studied activity cliffs 
using graphical methods of interpreting the landscape. 
They have given detailed specifications of cliffs [10–12]. 
The series of cliffs in the landscape is characterized as 
activity ridge when many structural analogs possess high 
activity variation [11, 12] and activity islands are used 
to specify the structurally similar compounds based on 
some descriptors [13]. Quantitative analysis of the struc-
ture activity relationships is of growing importance to 
researchers but known to be less effective for studying 
cliffs formed by analogs having little structural variation 
[3]. In previous work, quantitative analysis has relied 
mainly on measures such as—structure activity landscape 
index (SALI) and some algorithmic or statistical analysis 
[12]. However, these methods and specifications of cliff 
(or distinctive) interactions are rather insufficient as they 
are threshold driven and offer a descriptive analysis of 
patterns. Moreover, increased activity variation may not 
indicate decrease in activity similarity particularly when 
the magnitude of similarity is determined by number of 
commonly active targets. Previous studies have not dif-
ferentiated between these two measures of quantifying 
the aberrations. Further, the magnitude of data consid-
ered for the analysis can significantly change the patterns 
of drug activity on targets and the inferences on similar 
activity [14].
This paper attempts to provide a mathematical basis of 
the extreme deviations observed. It would facilitate iden-
tification of distinctive interactions on different scales 
of measurements. The paper introduces a probabilistic 
analysis of the pharmacological topography and uses two 
measures of activity (similarity, s and variation, d) jointly 
with the corresponding chemical similarity c to investi-
gate distinctiveness. The measures are proportional to 
Jaccard index and represent weighted networks of drugs 
[15, 16]. The weights of the connections between drugs 
represent the strengths of their interactions. Pairwise 
activity similarity, s refers specifically to the number of 
commonly active targets of two drugs. Using probability 
distributions of s, d, c we identify medicinal categories 
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involved in the highly distinctive interactions. The pre-
dicted probabilities of s and d jointly with c are computed. 
This gives the probability of distinctiveness at varying 
levels. The level of distinctiveness of a pair of drugs (or 
drug interaction) is specified according to the magni-
tudes of the attributes s, d, c for that pair. We find that 
the choice of the measurement (low s or high d) affects 
the interpretation of distinctiveness and the topogra-
phy. These measures could impact the way in which we 
interpret the relation between two drugs in terms of their 
selectivity. Drug selectivity is a property exhibited by a 
drug when it is active on a protein as opposed to different 
proteins [3, 4]. Thus s and d can indicate how commonly 
and uncommonly selective the pairs of drugs are, but this 
is not necessary.
Highly distinctive interactions can be filtered as struc-
turally similar drugs having either the most variant or 
least similar activity profiles. Intriguingly, there is little 
consensus on the distinctive interactions filtered with 
the two measures. We study the diversity of pharmaco-
logical space using a large network of drugs and protein 
targets. The similarity principle is contradicted in the 
region where cliffs are present, however, the sizes of these 
cliffs are variable [12]. Structural or chemical similar-
ity of two drugs (c) corresponds to a divergence of both 
the nature and size of their activity profiles. Plausibly, a 
slight change in choice of molecules results in a signifi-
cantly dissimilar analog of a drug while not altering its 
functioning on many targets. Conversely, the activity 
profiles of new medicines may be vastly different from 
those of their chemical analogs. The propensity of dis-
tinctiveness in drug interactions has implications on drug 
substitution. The discovery of multi-target drugs is ben-
eficial for drug repurposing and it can result from small 
structural changes, which would affect distinctiveness 
of pairs of drugs. The method of analyzing distinctive-
ness is, therefore, important. Through a rigorous quan-
titative assessment of the activity landscape, this analysis 
aims to contribute not only to drug design but also to the 
decision making of the pharmacologists. Practitioners 
can apply these methods and criteria to classify the drug 
interactions as distinctive.
In the present pharmacological space, distinctive inter-
actions are more probable than non-distinctive interac-
tions. Non-distinctive interactions are regular as they 
conform to the similarity principle. Distinguishing among 
the distinctive interactions requires precision. The range 
of d is much higher than that of s. Quantitative compari-
son of the landscape reveals that structural and biologi-
cal similarities, two a priori independent manifestations 
of drug interactions, are unevenly associated and maybe 
complementary. The presence of distinctiveness is high-
lighted by both s and d. As chemical similarity increases, 
both measures decrease. However, the decrease in s is 
more significant than that in d, as d maintains its above 
average value. We show that activity variation is a more 
suitable measure for characterization of the pharmaco-
logical interaction space than activity similarity. Intermit-
tent rises in d with chemical similarity maybe interpreted 
as activity canyons or gorges of varying levels. In this rep-
resentation, the rises in both measures can be assessed 
relative to their respective ranges of magnitudes and 
compared across all pairs. The rises in activity similarity 
and variation are interpreted as increase in non-distinc-
tiveness and distinctiveness respectively, characterized as 
activity canyons instead of cliffs. Therefore, distinctive-
ness is a general term that may represent abrupt devia-
tions in the landscape as cliffs or canyons depending on 
the method of measurement. Moreover, the canyon rep-
resentation allows for the quantitative analysis of ‘how 
distinctive and how probable?’, demarcating the pharma-
cological subspace for finding distinctiveness. These rises 
in activity variation are probable all along the chemical 
space and more distinct than drops in s. The predicted 
probability model introduced in this paper helps in iden-
tifying distinctive interactions and the probability of their 
occurrence in the landscape. It also helps in identifying 
distinctive drug associations that are not only significant 
and rare but also less apparent.
Results and discussion
The drug network
We analyzed the bipartite graph of 1354 drugs and 1596 
proteins as their targets listed in the Drugbank database. 
In this graph, a link between a drug and protein signi-
fies that the drug is active on that protein. An interac-
tion between a pair of drugs indicates their association or 
connection based on whether or not they have a common 
target. For further analysis of measurements of similar-
ity and variation in activity between drugs, we use infor-
mation on activity of drugs on proteins to construct a 
weighted adjacency matrix. Every element of this matrix 
gives the pairwise weight measures of the interactions. 
An interaction is quantified in terms of the number of 
common targets (s) or the number of proteins on which 
the activity of two drugs differs (d). Thus both s and d are 
proportional to the Jaccard index used for calculation of 
chemical or structural similarity c. “Data: drugs, proteins, 
chemical similarity” section describes the data on drugs, 
proteins, activity, c used for this analysis.
Interactions in the pharmacological topography: from cliffs 
to canyons
In this paper, an interaction between two drugs refers 
to the difference or similarity of activity of the drugs on 
the same protein. It is attributed a weight equal to the 
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number of common or uncommon targets of the drugs. 
The discontinuities arising in the activity landscape 
due to sharp drops in similar activity along the chemi-
cal space represent drug interactions that are distinctive 
in nature [3, 4, 10–12]. They are not regular as they do 
not conform to the similarity principle. In other words, 
an interaction is distinctive when structurally similar 
drugs tend to behave oppositely on the same proteins. 
There may be two alternative specifications of a distinc-
tive interaction in any pharmacological space. One, a pair 
of structurally similar drugs could have low similarity in 
activity. Two, the activity profiles of two structurally sim-
ilar drugs may be highly dissimilar or variant. These are 
used alternatively for characterizing the well known phe-
nomenon of activity cliff [3, 4, 10–12]. However, as we 
show here, this choice of measurement becomes crucial 
if s is measured by only the commonly active targets of 
drugs and ignores the commonly unresponsive proteins. 
Thus, the activity variation may not totally indicate the 
magnitude of similarity of drugs. We determine which 
of these behaviors is dominant in the present interaction 
space using the measures of s, d. We study their patterns 
with change in chemical similarity, and the implications 
for distinctiveness.
Similarity and variation
The weighted adjacency matrices S and D of drug–drug 
interactions measure the magnitude of similarity and dif-
ference or variation in activity of drug pairs respectively 
(“S and D” section). In the given pharmacological space, 
0 ≤ Sij ≤ 28; 0 ≤ Dij ≤ 114. These interaction weights 
representing elements of S and D are denoted by s and d 
respectively.
The measures applied facilitate the comparative analy-
sis as they augment the differences in their magnitudes 
and ranges.
Comparison in the chemical space
We examine how the measures vary on all pairs of drugs 
in different ranges of chemical similarity, c. Figure 1 illus-
trates the comparison of s and d for the structure–activ-
ity association in progressing windows of c. Detailed 
inspection suggests that although the averages of both s 
and d are more or less constant over the chemical space, 
in every window, the fractions of the weights of d found 
above average remain higher than fractions of weights of 
s found above average. These d weights tend to be higher 
in magnitude than s weights owing to constructions of s, 
d. While both s and d decline with c overall, it must be 
noted that the decrease in s occurs rather gradually and 
hence the cliff representation may be deficient. Further, 
we compare the density of magnitudes (or number of 
points) found above average for s and d across each row 
of plots in Fig.  1. In all the subfigures, and particularly 
the ones in the intermediate region of the chemical space 
0.3 ≤ c ≤ 0.65, it is clear that region marked by above 
average d is more abundantly occupied by points than 
the corresponding region for s. This implies that a pair of 
structurally similar drugs is more likely to possess highly 
variant than highly similar activity.
Intermittent spikes in activity variation occur in the 
intermediate range of chemical similarity c ∈ [0.3, 0.65] 
or c ∈ [0.4, 0.65] with a dense layer of points beneath. 
This feature can be used to reasonably delineate the 
structure versus activity graphs from the perspective of 
activity variation. Thus in terms of variation, the topog-
raphy maybe characterized as activity canyons or gorges 
depending on the steepness. This also applies to s but less 
distinctly.
Quantifying structure and activity
In general, medicinal chemistry has relied on quantifica-
tion of structure activity to obtain a function f such that—
change in physiological activity = f (change in structure) 
[3, 4]. Here we see that the nature of the function and 
hence the landscape characterization would depend on 
which of the measures (s or d) is considered for quan-
tifying biological activity. We are interested in the two 
dimensional interactions relating structure (c) and activ-
ity (s or d). Measures like SALI have been applied to 
quantify activity cliffs [12]. However, high SALI could 
also arise from high c (and low d) or low c (and high d). 
The overall score can be misleading for identification of 
distinctive interactions with high c and high d. We there-
fore present a probabilistic analysis of the each of the 
measures s and d jointly with c. This informs us not only 
the significance of cliffs but also where (if at all) they are 
found in the chemical space. In the canyon representa-
tion above, intermittent rises in the measures charac-
terize distinctive interactions. The main purpose of this 
representation is for finding the probability of occurrence 
of various levels of (extreme) deviations. In other words, 
for every pair of drugs, it quantifies: how distinctive and 
how probable?
Predicted probability
We compute joint probability of structural similarity 
with activity variation and with activity similarity, that is, 
the probabilities of (c and s) and (c and d). This analysis 
is based on the distributions of c, s, d weights represent-
ing all pairs of drugs. Figure 2 shows the different kinds 
of probability distributions of drug–drug interactions in 
terms of P(S = s), P(D = d), P(C = c). While s and c con-
form to a power law probability distribution, d follows 
an exponential distribution indicating that on the axis of 
d, the probability of high magnitudes diminishes greatly. 
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This indicates that probability of finding extremely large 
variation (d) diminishes much more than the probability 
of finding very large s weights, however, the magnitudes 
of d are much higher than those of s when c ≥ 0.3. Fur-
ther, the power law exponents of c, s indicate that the 
variance of c is much higher than that of s, implying that 
s is more or less homogeneously distributed in the inter-
action space. “Probability distributions” section gives the 
mathematical forms and the estimation of the exponents 
(or constants). Note that the distributions found are 
approximations used to provide a generalized prediction 
of the propensity of distinctiveness.
In this interaction based predicted probabil-
ity model, the joint probability P(s = s0 ∩ c = c0) or 
P(d = d0 ∩ c = c0) for each pair of drugs specifies the 
chance of finding the level of distinctiveness shown by 
the interaction between that pair of drugs. See “Joint 
probability computation” section for computation.
We find that the observed average (standard devia-
tion) of s and d weights is 0.056 (0.5) and 7.44 (7.01) 
respectively. We compare the two measures by com-
puting the predicted probabilities of s and d above their 
respective averages P((s ≥ µs) ∩ (c1 ≤ c ≤ c2)) and 
P((d ≥ µd) ∩ (c1 ≤ c ≤ c2)). Details of this procedure 
are given in “Joint probability computation” section. 
The probabilities calculated with the model for the cat-
egories j  =  0, 1,…, 9 for d are almost consistently and 
significantly higher than those for s. When they are not 
higher, the difference is insignificant. We also compare 
the empirical probability of standardized scores of s and 
d being positive (above their averages). The probability 
of finding positive values of d is higher than that of s. It 
must be noted that c is considered at least equal to 0.3 
because c < 0.3 is not significant for any analysis. Ignor-
ing all pairs with c < 0.3 in this data, we have µs = 1.62, 
σs = 2.95, µd = 4.8, σd = 7.53.
Validation 1. We validate the predicted probability 
formulas (derived in “Joint probability computation” 
section) for the entire data of 1354 drugs by compar-
ing it with the observed probability for categories 
s ≥ µs + nσs and d ≥ µd + nσd taking c ≥ 0.3. For 
this purpose, we take observations and compute pre-
dictions at n= 0, 0.2, 0.4,…, 9. We use the averages 
and standard deviations for the entire (original) data 





























































Fig. 1 Pairwise weights of s (left) and d (right) with c in four overlapping ranges of c (topmost to bottom in order) of [0.3, 0.5], [0.4, 0.6], [0.5, 0.7], [0.6, 
0.8]. The red lines in each subfigure represent the corresponding averages of s and d in the respective ranges of c. The units of s and d are given as 
the number of common and uncommon targets respectively. 0 ≤ s ≤ 28, 0 ≤ d ≤ 114. Chemical similarity, c is given as 0 ≤ c ≤ 1
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and compute RMSE (see “Root mean square error” 
section) for judging the agreement between the pre-
dicted probability (ppred) and observed probability 
(pobs) for s and d. This is as low as 0.0001 and 0.0006 
for calculations of d and s respectively. It is remark-
able that while generalized predictions are made with 
the assumption of independence of s and c, and, d 
and c on all pairs of drugs, they confirm the observed 
dominance of above average d values. Figure 3 shows 
the agreement between observed and predicted val-
ues for d.
2. We now validate the predictions of the probability of 
distinctiveness using the system of drugs of the nerv-
ous system. This system consists of data on activity 
of 146 drugs on 219 protein targets. The probability 
distributions of interaction weights measured using 
pairwise s, d, c values for this system are similar to 
those shown in Fig. 2 but the patterns are not iden-
tical. While the probability distribution of c is the 
same as that obtained above, the distributions of s 
and d show approximately similar patterns as there 
may be some deviations. As before, we compare the 
observed probabilities with the predicted probabili-
ties using the formulas, for categories s ≥ µs + nσs , 
d ≥ µd + nσd taking c ≥ 0.3. Using the informa-
tion for this drug ensemble cmin = 0.0089, smin = 1, 
dmin = 0,µs = 1.18, σs = 3.63,µd = 16.67, σd = 13.39 , 
we show in Fig.  4 the agreement between observa-
tions and predictions for d. RMSE is 0.002 and 0.0006 
for s and d calculations respectively. It is crucial to 
note that there is good agreement between obser-
vations and predictions despite the deviations from 
the assumptions and conditions involved in the con-
struction of the formulas.
Hypotheses testing
We establish whether or not variation in activity domi-
nates similarity in activity by comparing observed prob-
abilities (p1, p2) in regions spanning the chemical space 
0.3 ≤ c ≤ 1. The tests are listed below. Tests 1–3 show 
the comparison for the region 0.3 ≤ c ≤ 1. Comparisons 
between different regions are given in tests 4–5. Test 6 
gives the significance of variation as a refined filter of rare 
distinctive interactions. “McNemar’s test for comparing 
proportions of s and d in the same chemical space” and 
“Paired t test” sections describe the two statistical tests 
applied. Reported below are the test results along with 
the significance level ρ,
1. 
2. 
p1 = P(c ≥ 0.3 ∩ s ≥ µs),
p2 = P(c ≥ 0.3 ∩ d ≥ µd)
p2 > p1, ρ < 0.01
p1 = P(0.3 ≤ c ≤ 0.65 ∩ s ≥ µs),
p2 = P(0.3 ≤ c ≤ 0.65 ∩ d ≥ µd)
p2 > p1, ρ < 0.01
Fig. 2 (Top) Probability of pairwise chemical or structural similarities 
P(C = c) on a log–log plot. The straight line approximates power law 
behavior on a range of c with exponent 3.6±0.14. (Middle) Probability 
of number of similar activities P(S = s) on log–log plot. The straight 
line approximates power law behavior on a range of s with exponent 
2.37±0.15. (Bottom) Probability of number of dissimilar activities or 
variation P(D = d) on a semilog plot. The straight line approximates 











































Fig. 3 Observed and predicted probabilities (scaled) for 
d ≥ µd + nσd and c ≥ 0.3 plotted with n using the original data (left). 
Observed versus predicted probabilities showing a good agreement 
(right)





Results of the first three tests confirm that variant 
activity behavior dominates the similar activity behav-
ior of the drug pairs consistently in the chemical space. 
The probability of finding above average d magnitudes 
is more than that of finding above average s magnitudes 
in the region c ≥ 0.65, but the difference is less sig-
nificant. The intermediate region of the chemical space 
0.3 ≤ c ≤ 0.65 marks the transitional regime when struc-
tural similarity starts being positively associated with d 
more than with s. Distinctiveness emerges here. Tests 4, 
5 indicate that d and s decrease with increase in c. How-
ever, d significantly dominates s in both proportion and 
magnitude particularly in the intermediate chemical 
region. We apply paired t test (“Paired t test” section) to 
compare these probabilities as they specify the effect of 
changing the level or range of c of interactions on their s 
p1 = P(c ≥ 0.65 ∩ s ≥ µs),
p2 = P(c ≥ 0.65 ∩ d ≥ µd)
p2 > p1, ρ ≈ 0.1
p1 = P(0.3 ≤ c ≤ 0.65 ∩ s ≥ µs),
p2 = P(c ≥ 0.65 ∩ s ≥ µs)
p1 > p2, ρ < 0.05
p1 = P(0.3 ≤ c ≤ 0.65 ∩ d ≥ µd),
p2 = P(c ≥ 0.65 ∩ d ≥ µd)
p1 > p2, ρ < 0.05
p1 = P(c ≥ 0.65 ∩ s ≤ µs),
p2 = P(c ≥ 0.65 ∩ d ≥ µd),
p1 > p2, ρ < 0.01.
and d weights. Test 6 establishes the advantage of d as a 
potential filter of distinctive interactions. Few above aver-
age d weights (32.5%) are higher in magnitude than 75% 
of below average s weights (Fig. 5i–iii). We identify all the 
rarely occurring distinctive interactions, most of which 
are not revealed with s but are crucial for characteriza-
tion of activity landscape. Further, d yields distinctiveness 
at multiple levels of hierarchy set by criterion of the num-
ber of standard deviations above the average.
Most distinctive interactions occur between vitamins 
and medicines curing ailments of classes such as cen-
tral nervous system or dermatological in nature. Several 
less similar interactions filtered as distinctive, include 
compound pairs from distinct classes. Figure 6i, ii shows 
structural similarity of Sitagliptin and Nefazodane that 
affect insulin release and central nervous system, respec-
tively. Interestingly, highly variant interactions are fewer 
and more distinctive as they include drugs and their 
structural analogs belonging to the same class but per-
forming intricately different functions. Figure  6iii–vi 
shows structurally similar Loxapine and Amoxapine 
affect the nervous system but Amoxapine is more ver-
satile. Felodipine and Clevidipine are analogs for cur-
ing hypertension but Clevidipine treatment is more 
advanced. Thus, activity variation calculations are advan-
tageous for identifying medicinal analogs that provide 
more specialized treatments for same kinds of ailments. 
We find that activities of such medicinal analogs typically 
vary a lot.
Tests 1–3 and 6 use McNemar test (“McNemar’s test 
for comparing proportions of s and d in the same chemi-
cal space” section). Test 6 compares d as a filter for 
highly distinctive drug interactions with s. We compare 
the probabilities p1 = P(c ≥ 0.65 ∩ s ≤ µs − nσs) and 
p2 = P(c ≥ 0.65 ∩ d ≥ µd + nσd), n = 0, 1, 2…. For n=1, 
p1 = 0 and p2 = 11120 = 0.09. The d measure yields maxi-
mally distinctive interactions as n is increased, implying 
distinctiveness at multiple levels. Figure 5iii indicates this 
and for n=1 we report the pairs of drugs that are most 
distinctive. The proportion and nature of interactions fil-
tered are significantly different from that obtained with s.
Conclusions
This paper makes two contributions  mainly. One is a 
methodological contribution as we provide a mathemati-
cal basis for identifying distinctive interactions, com-
monly studied as activity cliffs in literature. The predicted 
probability analysis we have introduced is based on sim-
ple assumptions but predicts the overall distinctiveness 
in various chemical regions to a reasonable accuracy. 
Further, it is able to predict the distinctiveness observed 
in a pharmacological space that may not be identical 
to the one considered for its construction. The second 


















Fig. 4 Observed and predicted probabilities (scaled) for 
d ≥ µd + nσd and c ≥ 0.3 plotted with n for the drugs of the nervous 
system
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contribution is that this paper provides a new characteri-
zation of the pharmacological topography in the form of 
canyons. It is associated with the probabilistic analysis of 
distinctiveness and helps to filter the drug interactions 
at varying levels of distinctiveness and non-distinctive-
ness. This representation is appropriate for a probabilis-
tic analysis because we use two measures—s and d that 
vary on highly different scales in the data. It identifies 
distinctive interactions and the region of the chemi-
cal space to find them. This methodology aims to rigor-
ously quantify distinctiveness which can occur in diverse 
forms. This is particularly helpful as the presence of these 
deviations is known to hinder the quantitative structure 
activity modeling. Moreover, when similarity of activity 
is considered as given by the commonly active targets, 
some medicinal pairs may show both distinctiveness and 
Fig. 5 i Network of 91 distinctive interactions determined by s below average. ii Network of 39 distinctive interactions determined by d above 
average. iii Network of 11 distinctive interactions determined by d by calculation for d ≥ µd + σd . The medicine pairs are (Lysine–Ornithone), 
(Adenosine monophosphate–Adenosine triphosphate), (Vitamin A–Alitretinoin), (Vitamin A–Tretinoin), (Vitamin A–Isotretinoin), (Propoiomazine–
Aceprometazine), (Loxapine–Amoxapine), (Dicloxacillin–Cloxacillin), (Pseudoephidrine–Ephedrine), (Tioconazole–Miconazole), (Felodipine–Clevidi-
pine)
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non-distinctiveness and the cliff representation is not 
sufficient.
Activity cliffs have been studied in detail in past 
research. These aberrations make it harder to coherently 
generalize the quantitative association between changes 
in physiological activity and structure, which is vital for 
medicinal chemists. Methods applied can impact the 
decision process of preparing fresh drugs and drug devel-
opment through identification of distinctive pairs.
The interpretation of the topography of pharmacologi-
cal interaction space can vary according to the choice of 
measurement of c, s, d. We illustrate this with a probabil-
istic analysis of the pharmacological space which consid-
ers the probability of each of the measures s and d jointly 
with c. The consistency between observations and pre-
dictions corroborates that structural (c) and biological (s 
or d) properties can be considered as independently gen-
erated for studying the discontinuities in the landscape. 
Fig. 6 i Sitagliptin—used for control of type 2 diabetes mellitus, increased release of insulin. ii Nefazodone—analogous to Sitagliptin but affects 
the nervous system, has a palliative action. iii Loxapine-antipsychotic drug. iv Amoxapine—analogous to Loxapine but used for many other neu-
rotic disorders and sedation. v Feldopine—calcium channel blocker for moderate hypertension. vi Clevidipine—analogous to Feldopine, is calcium 
channel blocker, but for advanced treatment of blood pressure
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A distinctive interaction can be measured either as high 
c, d or high c and low s. The almost contrasting construc-
tion of both measures results in a much higher range and 
distribution of magnitudes of d than of s. This affects the 
quantitative assessment of the interaction landscape, 
particularly for distinguishing structure–activity func-
tions displayed by drugs. We establish using probability 
distributions of interaction attributes that it is less signifi-
cantly likely for a pair of drugs with high structural simi-
larity to act similarly than oppositely on a target. Further, 
the decrease in similar activity along the chemical space 
lacks the steepness of a cliff. In the given pharmacologi-
cal space, high d dominates the chemical space in terms 
of not only magnitudes but also the probabilities. This 
behavior is mostly observed in the intermediate range of 
c, which we refer to as a transitional regime as it marks 
the increasing significance of d.
As c increases, interactions corresponding to high d are 
relatively rare and more distinctive than those of low s. 
This facilitates preparation of analogs for intricately spec-
ified treatments. Low s interactions can occur between 
drugs affecting different classes. However, distinctive 
interactions of high d are rarer and occur between struc-
tural analogs aimed to treat same kinds of ailments with 
increasingly intricate specifications. Such analogs provid-
ing advanced or versatile treatments of same kinds of ail-
ments vary highly in their activity profiles. It is important 
to note that such associations are identified with high 
activity variation instead of low similarity.
Given the complex nature of structure–activity rela-
tionship study, a perfect conceptualization of the phar-
macological topography may be hard. This analysis aims 
to suggest an alternative characterization resulting from 
mathematical and statistical formulations. A crowded 
valley of magnitudes with intermittent spikes of variation 
in the chemical subspaces, may be characterized as activ-
ity canyons or gorges. In a way this can be an encourag-
ing sign for diversity in drug development. For instance, 
if a minor change in structure gives rise to an analog, 
then the two may be active on different kinds of targets 
more often than not. The sizes of their activity profiles 
may also be quite different. The methods provide a basis 
for practitioners and pharmacologists to identify distinc-
tive interactions and the region of chemical space that 
they are probable to be observed in.
Methods
Data: drugs, proteins, chemical similarity
We use categorical binary activity results of 1354 drugs 
on 1596 protein targets. The activity information is given 
as binary attributes, Ai(k) = 1 if a drug i is active on pro-
tein k and 0 if the drug is not active. This constitutes the 
activity profile of drug i. Chemical similarity of drugs is 
computed pairwise with tanimoto similarity method [17]. 
The weighted network of N = 1354 drugs, C, has N × N  
weighted adjacency matrix. The elements of the matrix, 
Cij give the chemical similarity of the pair of drugs and 
0 ≤ Cij ≤ 1.
Pairwise similarity and variation in activity of drugs
S and D
S—If Ai and Aj are activity profiles of drugs i,j, that 
is the proteins k for which Ai(k) =1 and Aj(k) =1, then 
Sij =
∣∣Ai(k) ∩ Aj(k)∣∣. Here S has N × N  weighted adja-
cency matrix. We denote the similarity weights or mag-
nitudes as s. The commonly unresponsive proteins are 
ignored. Every element of the matrix denotes the weight 
of the connection or the interaction between pairs of 
drugs.
D—Variation between the activity profiles of two 
drugs measures the number of differences in their binary 
attributes, that is the number of proteins on which they 
differ in activity. The weighted network D of pairwise 
distances of drugs N × N  weighted adjacency matrix 
Dij =
∣∣(Ai(k) ∩ Aj(k)) ∪ (Ai(k) ∩ Aj(k))∣∣. This is almost 
complement of S as we ignore the commonly unrespon-
sive proteins on all pairs of drugs while computing S. 
Both these measures [15, 16] are constructed along the 
lines of Jaccard similarity and distance coefficient with-
out normalization. We’re interested in constructions of S 
and D so as to make their magnitudes and variances dis-




Assuming continuous distributions for the pairwise 
weights as random variables for similarity (s), variation 
(d), chemical similarity (c), we write the mathematical 
forms of the normalized probability distributions as
P(s),P(c) are power law distributions and P(d) is 
exponential. The behaviors are shown in Fig.  2. The 
constants α, γ ,  are computed as regression coef-
ficients given as slopes of the straight lines in the 3 
plots shown in Fig.  2 with probability p shown on 
the vertical axis. The first two top figures for c and 
s are on a log–log scale, so that the straight lines 
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log (p(c)) = γ log (c)+ intercept. The straight line 
in Fig.  2 (bottom) is on a semi-log scale, given as 
log (p(d)) = d + intercept. Note that each of these 
regression equations implies that the probability in every 
case is proportional to eintercept. This does not affect the 
calculation of the slope constants. Here smin, cmin, dmin 
correspond to the minimum values of biological, struc-
tural similarity and variation respectively. We have 
dmin =  0 and for a well defined power-law distribution, 
we consider smin = 1, cmin = 0.004.
Joint probability computation
The joint probabilities using s and d are P(s = s0 ∩ c = c0) 
and P(d = d0 ∩ c = c0) respectively. s0, c0, d0 are param-
eters denoting magnitudes of s, c, d which we vary. In 
the same way, we can specify ranges of study s1 ≤ s ≤ s2 , 
c1 ≤ c ≤ c2, d1 ≤ d ≤ d2 and find the corresponding 
probabilities.
If structure and activity are independently generated, then 
predicted joint probabilities are given by
Proof As structure and activity are independently gener-
ated, using probability distributions of P(c) and P(s) from 
above, the joint probabilities approximate to
Similarly, using probability distributions of P(c) and 
P(d), we obtain
Solving Eqs. (1) and (2) we obtain









































P((c1 ≤ c ≤ c2) ∩ (s1 ≤ s ≤ s2))
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Equations (3) and (4) give the predicted probabilities of 
simultaneously finding structural and activity similarity, 
and, structural similarity and activity variation in a range, 
respectively.
We compare the two measures by computing the pre-
dicted probabilities of similarity and distance above 
their respective averages. We denote the average and 
standard deviation (respectively) of s as µs, σs and of 
d as µd, σd. This is given by comparing Eqs.  (3) and (4) 
taking smin = 1, cmin = 0.004, dmin = 0, s1 = µs, s2 = ∞, 
d1 = µd, d2 = ∞, in different ranges of [c1, c2] as [0.3,) 
[0.3, 0.65], [0.65,) for the purpose of integration. In the 
range of c ≥ 0.3, we have µs = 1.62, σs = 2.95, µd = 4.85, 
σd = 7.53. It must be noted that we compute the values of 
these averages and standard deviations for all progressing 
windows along the chemical space.
In order to compare s with d above their respective aver-
ages, we measure the predicted probability of finding 
s ≥ µs + nσs and d ≥ µd + nσd for n=0,1, 2… respectively, 
in the same chemical space. The standard deviations may also 
be increased in steps of 0.2. These are considered as meas-
urements for the categories P((s ≥ µs) ∩ (c1 ≤ c ≤ c2)) and 
P((d ≥ µd) ∩ (c1 ≤ c ≤ c2)) for similar and variant activi-
ties respectively. We also find the probabilities for standard-
ized data where all the values of s and d are subtracted from 
their averages and divided by their standard deviations for a 
certain chemical space. Then the comparison is between the 
probability of finding s and d above their average = 0 in a 
given chemical space.






j−1 , j = 1, 2 . . . Note that we 
compute the observed values by considering the number 
of pairs sharing both properties of being within the given 
range of c and s (or d). Thus P(s ∩ c) = P(s|c)P(c). If we 
find the joint probability of the two properties in a par-
ticular range of c then P(c) = 1.
Hypothesis testing
In order to test the significance of the difference between 
the observed probabilities associated with s and d, we 
apply two tests.
McNemar’s test for comparing proportions of s and d in the 
same chemical space
We use this test to compare the relative frequencies (or 
probabilities) of s and d above their averages in the same 
(4)
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chemical region c ∈ [c1, c2]. This test is suitable for com-
parisons of the [18] two measurements made on the same 
pairs. The contingency table for a given chemical region is
d ≥ µd d < µd
s ≥ µs n1 n2
s < µs n3 n4
If n1 + n2 + n3 + n4 = n, we test whether or not marginal 
probabilities are equal: n1+n2n =
n1+n3





The null and alternative hypotheses can be written as
H0: n2 = n3
H1: n2 < n3 (frequency of d ≥ µd is greater than that of 
s ≥ µs in the given chemical region)
We reject H0 in favor of H1 at the level of signifi-
cance ρ if (n2−n3)2n2+n3 > χ
2
1 , or if binomial probability 
P(X ≥ n3|n = n2 + n3, p = 0.5) ≤ ρ. The comparisons 
made here suit the design of the analysis, hence no cor-
rections are required. Further, ρ of the tests is sufficiently 
low for the tests to be significant after correction.
Paired t test
This test is used to compare the average of the differ- 
ence between probabilities p1 = P((c1 ≤ c ≤ c2)
⋂
 
(s ≥ µs + nσs)) and p2 = P
(
(c1 ≤ c ≤ c2)
⋂
(d ≥ µd+
nσd)) observed (pairwise) at n = 0, 1, … 8. We also sam-
ple the observations by increasing standard deviations 
in intervals of 0.2.  All the probabilities so computed can 
be generalized as p1 = P
(











. These probabilities 
represent the results obtained by two different measures of 
interaction distinctiveness—s, d. In this way, we consider 
the variation of probabilities in the space above the average 
sampled at increasing number of standard deviations.
We test the null hypothesis H0 of equality of probabili-
ties on average against one-sided alternative H1
H0:  = 0
H1: � < 0 or H1: � > 0
with the test statistic, t = �
σ�/n
 at significance level 
ρ = 0.05 for n −  1 d.f. Here  represents the vector of 
differences, p1 − p2, σ� is the standard deviation of  and 
sample size n = 9 here. The null hypothesis of no differ-
ence is rejected in favor of alternate H1 if the observed t 
is greater than the critical value of test statistic i.e. t > tc 
(0.05,8). We apply this for comparing probabilities of s 
and d in different chemical regions.
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